Clinical trial · Interventional
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
Exercise Therapy in Cancer Patients Hospitalized for COVID-19: A Digitized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the safety and tolerability of a 30-week aerobic exercise therapy program in cancer patients recovering from COVID-19. The study will look at whether the aerobic exercise therapy causes few or mild side effects in participants. Aerobic exercise is physical activity that uses the large muscle groups (muscles in your legs, buttocks, back, and chest) and can be performed for several minutes at a time. The aerobic exercise therapy being used in this study will be a walking program that will be adjusted so it matches participant fitness levels (how much exercise you can handle).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Coronavirus | — | UNRESOLVED | — |
| Covid19 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aerobic Exercise Therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants who were hospitalized for COVID-19
- description
- Participants will be post-cancer treatment patients who were hospitalized for COVID-19.
- interventionNames
- Other: Aerobic Exercise Therapy
Primary outcomes (1)
- measure
- Frequency of serious adverse events during study-related assessments
- timeFrame
- 30 weeks
- description
- Safety will be evaluated by the frequency of serious (i.e., life-threatening, hospitalization, significant incapacity, important medical events) adverse events during study-related assessments and exercise sessions according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 * Previously admitted to a hospital for Covid-19 * Discharged from hospital for at least 30 days * Previously treated for cancer at MSK * Interval of ≥ 12 months but ≤ 10 years following completion of primary non-hormonal anti-cancer therapy (current endocrine therapy and maintenance therapy allowed) * Space to house a treadmill at personal residence * Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) * Performing less than 90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self-report * If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study. * Women \<50 years old who are of child-bearing potential must have a negative pregnancy test within 14 days of enrollment. Exclusion Criteria: * Currently receiving home oxygen after discharge * Enrollment onto any other interventional investigational study * Current treatment for any other diagnosis of invasive cancer of any kind * Distant metastatic malignancy of any kind * Receiving non-hormonal anticancer therapy * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
References
Publications (1)
- DERIVEDScott JM, Qiu Z, Rahman J, Moskowitz CS, Michalski MG, Lehman S, Lee CP, Harrison J, Yu AF, Marouf A, Vardhana S, Boutros PC, Jones LW. Case Report: Decentralized trial of tolerability-adapted exercise therapy after severe Covid-19. Front Immunol. 2025 Apr 3;16:1529385. doi: 10.3389/fimmu.2025.1529385. eCollection 2025. PMID 40248705